Primary aldosteronism (PA) is associated with higher cardiovascular morbidity and mortality
rates than essential hypertension. The Japan Endocrine Society (JES) has developed an …

The Japan Endocrine Society (JES) attempted to develop guidelines for the diagnosis and
treatment of primary aldosteronism (PA). The Task Force Committee (TFC) was composed of …

Background There is conflicting evidence, relying on heterogeneous studies, as to whether
aldosterone excess is responsible for an increased risk of cardiovascular and …

Primary aldosteronism (PA), a common, albeit markedly underdiagnosed cause of curable
arterial hypertension, is characterized by plasma levels of aldosterone that are inappropriate …

Aldosterone producing adenoma and bilateral adrenal hyperplasia are the two most
common subtypes of primary aldosteronism (PA) that require targeted and distinct …

Background/Purpose Even though the increasing clinical recognition of primary
aldosteronism (PA) as a public health issue, its heightened risk profiles and the availability …

Numerous studies conducted in recent years have reported an increase in the prevalence of
primary aldosteronism (PA). This increase has arisen because of changes in our screening …

Objective: To develop clinical practice guidelines for the management of patients with
primary aldosteronism. Participants: The Task Force included a chair, selected by the …

Primary aldosteronism (PA) is the most common form of secondary hypertension (HTN), with
an estimated prevalence of 4% of hypertensive patients in primary care and around 10% of …

Primary aldosteronism (PA) is the most common secondary form of arterial hypertension,
with a particularly high prevalence among patients with resistant hypertension. Aldosterone …